The Federal Court has ordered that the makers of pain relief product Voltaren Osteo Gel pay $4.5 million in penalties for breaches of Australian Consumer Law.
In May 2019 the Federal Court accepted admissions by Novartis Consumer Health Australasia (Novartis) and GlaxoSmithKline Consumer Healthcare Australia (GSK) that they made false or misleading representations in the marketing of Voltaren Osteo Gel and Voltaren Emulgel pain relief products.
From January 2012 to March 2017, Novartis and then GSK marketed Osteo Gel as being specifically formulated and more effective than Emulgel in treating osteoarthritis related pain and inflammation even though both had the same active ingredients.
Osteo Gel was often sold at a higher price than Emulgel and the gels were often displayed next to each other at pharmacies and grocery stores.
The Australian Competition and Competition Commission (ACCC) commissioner Sarah Court says the claims that the Osteo Gel was more effective than Emulgel were "unacceptable".
“Voltaren Osteo Gel and Voltaren Emulgel were essentially the same gel and were equally effective in treating osteoarthritis symptoms," Court says.
“Novartis and GSK’s claims were particularly concerning because they set recommended retail prices for Osteo Gel above that of Emulgel, by up to 16%, and consumers were potentially misled into paying more for an identical product believing it was more effective."
The misleading claims were made on product packaging and the Voltaren website by both companies and Novartis also made the claims on the My Joint Health website.
GSK acquired Novartis’ portfolio of Voltaren products in March 2016 and has been responsible for marketing and selling Voltaren products since June 1, 2016, after a three month transitional period.
In March 2017, GSK amended the Osteo Gel packaging to include the words ‘Same effective formula as Voltaren Emulgel’.
The court did not find that the revised packaging was misleading.
GSK stopped supplying the Osteo Gel product to retailers in May 2018.
Have something to say on this? Share your views in the comments section below. Or if you have a news story or tip-off, drop us a line at adnews@yaffa.com.au
Sign up to the AdNews newsletter, like us on Facebook or follow us on Twitter for breaking stories and campaigns throughout the day.